Home > Insider Trading > Filing (0001415889-24-009019)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1805097	D. Rahul Ballal	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-20	13,278	$5.52	35,619	No	4	M	Direct
Common Stock	Disposition	2024-03-20	13,278	$19.16	22,341	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-03-20	13,278	$0.00	13,278	$5.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
19,571		2032-01-27	No	4	M	Direct

Footnotes

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings.
This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.